Clinical-stage developers of psilocybin, MDMA, and next-generation psychedelic compounds.
Ticker
Company
Last
Change
%
Compass Pathways
7.98
−0.29
−3.51%
CMPSCompass PathwaysNasdaq · USDPsychedelics
$7.98−3.51%Nov 17, 2026, 4:00 PM ET · delayed
Open
$8.19
Day high
$8.41
Day low
$7.81
Volume
2.69M
Mkt cap
$1.13B
52w range
$4.88–$15.87
Price · last 1M
Loading chart…
Pipeline
CompoundIndicationAgencyPhase
COMP360 psilocybin
Treatment-resistant depression
FDA
Filed
Status Rolling NDA submission completed November 9, 2026; FDA has not announced acceptance for review. Holds a National Priority Voucher (FDA review target 1-2 months). Company expects launch in H1 2027, subject to FDA approval and DEA and state rescheduling.
Latest milestone · Nov 9, 2026 NDA submission completed; FDA acceptance for review not yet announced (Compass Pathways press release, 2026-11-09 (company investor-relations site))
Status Phase 2 signal-detection topline reported March 2026 (adjunct to standard of care)
Latest milestone · Mar 5, 2026 Topline results announced from the Phase 2 HLP004-002 study in generalized anxiety disorder (Helus Pharma MD&A for the quarter ended 2026-06-30 (Form 6-K, Exhibit 99.2))
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
GH Research
18.27
−0.48
−2.56%
GHRSGH ResearchNasdaq · USDPsychedelics
$18.27−2.56%Nov 17, 2026, 4:00 PM ET · delayed
Open
$18.48
Day high
$18.48
Day low
$17.57
Volume
324.2K
Mkt cap
$1.25B
52w range
$12.04–$31.44
Price · last 1M
Loading chart…
Pipeline
CompoundIndicationAgencyPhase
GH001 (inhaled mebufotenin)
Treatment-resistant depression
FDA
Ph. 2
Status Phase 2b positive; FDA written responses confirm CMC and device plans appear Phase 3 ready; pivotal program initiation targeted in 2026
Latest milestone · Aug 6, 2026 FDA written responses (received July 2026) confirmed CMC and device plans appear Phase 3 ready; initiation of the pivotal program targeted in 2026 (GH Research second-quarter 2026 results press release (Form 6-K, Exhibit 99.3))
Established and emerging makers of antidepressants, antipsychotics, and novel-mechanism CNS drugs.
Ticker
Company
Last
Change
%
Supernus, Inc. (formerly Indivior)
29.04
+0.21
+0.73%
SUPNSupernus, Inc. (formerly Indivior)Nasdaq · USDPharma
$29.04+0.73%Nov 17, 2026, 4:00 PM ET · delayed
Day change, market cap and 52-week range are not shown. Supernus, Inc., formerly Indivior, began trading as SUPN on Nov 3, 2026, after the Nov 2 merger, and the data provider's figures for the first sessions are not comparable with earlier prices.
Open
$28.72
Day high
$29.69
Day low
$28.45
Volume
2.81M
Price · last 1M
Loading chart…
Prices before Nov 3, 2026 are for the same shares when they traded as INDV. They are not adjusted for the $8.13-per-share special dividend declared Sept 16, 2026 (record date Oct 30) or for the merger, so a step down from Nov 3 is not a like-for-like price change.
Tracked mental-health programs
CompoundIndicationAgencyPhase
Zuranolone (Zurzuvae)
Postpartum depression
FDA
Approved
Status Marketed for PPD; not approved for MDD in the U.S.
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
Axsome Therapeutics
135.95
−1.06
−0.77%
AXSMAxsome TherapeuticsNasdaq · USDPharma
$135.95−0.77%Nov 17, 2026, 4:00 PM ET · delayed
Open
$136.36
Day high
$137.46
Day low
$134.67
Volume
518.1K
Mkt cap
$7.15B
52w range
$123.00–$260.19
Price · last 1M
Loading chart…
Tracked mental-health programs
CompoundIndicationAgencyPhase
AXS-05 (Auvelity)
Major depressive disorder
FDA
Approved
Status Marketed
AXS-05 (Auvelity)
Agitation associated with dementia due to Alzheimer's disease
FDA
Approved
Status FDA approved April 2026
Latest milestone · Apr 30, 2026 FDA approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease (Axsome Therapeutics press release (Form 8-K, Exhibit 99.1))
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
Acadia Pharmaceuticals
18.32
−0.35
−1.87%
ACADAcadia PharmaceuticalsNasdaq · USDPharma
$18.32−1.87%Nov 17, 2026, 4:00 PM ET · delayed
Open
$18.54
Day high
$18.73
Day low
$17.94
Volume
1.53M
Mkt cap
$3.17B
52w range
$15.86–$30.96
Price · last 1M
Loading chart…
Tracked mental-health programs
CompoundIndicationAgencyPhase
Remlifanserin (formerly ACP-204)
Alzheimer's disease psychosis
FDA
Ph. 3
Status Phase 2 portion of RADIANT narrowly missed its primary endpoint (p=0.0603); company plans to continue its two ongoing Phase 3 studies in ADP, without the 30 mg arm; FDA Fast Track granted July 2026; Phase 2 in Lewy body dementia psychosis ongoing
Latest milestone · Sep 24, 2026 Phase 2 RADIANT topline: primary endpoint narrowly missed (SAPS-H+D p=0.0603); company plans to continue enrolling its two ongoing Phase 3 studies and remove the 30 mg arm (Acadia Pharmaceuticals press release (Form 8-K, Exhibit 99.1))
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
Eli Lilly
1415.55
−16.12
−1.13%
LLYEli LillyNYSE · USDPharma
$1415.55−1.13%Nov 17, 2026, 4:01 PM ET · delayed
Open
$1415.99
Day high
$1432.28
Day low
$1401.66
Volume
2.48M
Mkt cap
$1.26T
52w range
$850.51–$1475.25
Price · last 1M
Loading chart…
Tracked mental-health programs
CompoundIndicationAgencyPhase
Brenipatide (LY3537031)
Major depressive disorder; alcohol use disorder
Ph. 3
Status Phase 3 recruiting in MDD and alcohol use disorder; Phase 2 in bipolar disorder and schizophrenia
BPL-003 (intranasal mebufotenin)
Treatment-resistant depression
FDA
Ph. 3
Status Phase 3 initiated; Lilly acquisition closed Sept 11, 2026
Latest milestone · Sep 11, 2026 Lilly completed its acquisition of AtaiBeckley, whose lead program BPL-003 (FDA Breakthrough Therapy designation) has initiated Phase 3 activities (AtaiBeckley Form 8-K (Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03 and 9.01))
VLS-01 (buccal DMT)
Treatment-resistant depression
Ph. 2
Status Phase 2b Elumina study in TRD: last patient dosed; topline results anticipated Q4 2026
Latest milestone · Aug 11, 2026 Phase 2b Elumina study in TRD: last patient dosed; topline results anticipated in Q4 2026 (AtaiBeckley Form 10-Q for the quarter ended 2026-06-30)
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
Johnson & Johnson
278.70
−3.85
−1.36%
JNJJohnson & JohnsonNYSE · USDPharma
$278.70−1.36%Nov 17, 2026, 4:00 PM ET · delayed
Open
$278.99
Day high
$281.72
Day low
$277.56
Volume
8.06M
Mkt cap
$670.92B
52w range
$198.53–$290.25
Price · last 1M
Loading chart…
Tracked mental-health programs
CompoundIndicationAgencyPhase
Esketamine (Spravato)
Treatment-resistant depression
FDA
Approved
Status FDA approved as monotherapy for adults with treatment-resistant depression (January 2025)
Latest milestone · Jan 21, 2025 FDA approved SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression (Johnson & Johnson press release, January 21, 2025)
Seltorexant
Major depressive disorder with insomnia symptoms
Ph. 3
Status MDD3001 positive; MDD3005 vs quetiapine XR missed primary endpoint (Sept 2025); additional Phase 3 recruiting
Latest milestone · Sep 22, 2025 Phase 3 MDD3005 against quetiapine XR: numerically greater 26-week response (57.4% vs 53.4%), primary endpoint not met (Johnson & Johnson press release, September 22, 2025)
Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed.
AbbVie
292.82
−1.73
−0.59%
ABBVAbbVieNYSE · USDPharma
$292.82−0.59%Nov 17, 2026, 4:03 PM ET · delayed
Open
$291.50
Day high
$294.06
Day low
$291.00
Volume
3.93M
Mkt cap
$517.59B
52w range
$190.75–$302.93
Price · last 1M
Loading chart…
Tracked mental-health programs
CompoundIndicationAgencyPhase
Emraclidine
Schizophrenia
Ph. 2
Status Phase 2 EMPOWER trials missed their primary endpoint; AbbVie recorded a $4.5B impairment. A separate Phase 2 schizophrenia study remains ongoing.